A review of the first year of Medicare coverage of erythropoietin. by Griffiths, R, Powe, N, Greer, J, de Lissovoy, G, Anderson, G, Whelton, P, Watson, A, Eggers, P

Early dosing practices and effectiveness of recombinant human erythropoietin. by Powe, N, Griffiths, R, Greer, J, Watson, A, Anderson, G, de Lissovoy, G, Herbert, R, Eggers, P, Milam, R, Whelton, P

Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval. by Powe, N, Griffiths, R, de Lissovoy, G, Anderson, G, Watson, A, Greer, J, Herbert, R, Eggers, P, Milam, R, Whelton, P

The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients. by de Lissovoy, G, Powe, N, Griffiths, R, Watson, A, Anderson, G, Greer, J, Herbert, R, Eggers, P, Milam, R, Whelton, P